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Selected Care Process or 
outcome 
Aspirin ~24 hrs 
Beta-Blocker <24 hrs 
Heparin ~24 hrs 
Clopidogrel<24 hrs 
GP Ilb-llla <24 hrs 
Beta-Blocker at D/C 
ACE Inhibitor at D/C 
Lipid-Lowering Drug at DIG 
Cardiac Catheterization 
In-Hospital Mortality 
Cards 
MD 
92% 
77% 
86% 
42% 
39% 
61% 
60% 
79% 
77% 
3.3% 
Non-Cards Adjusted OR’ (95% 
MD Cf) 
86% 1.34(1.2-1.5) 
73% 1.32 (1.2-l .4) 
70% 1.69 (1.4-2.0) 
26% 1.63 (1.5-1.6) 
21% 1.95 (1.7-2.2) 
79% 1.20 (1.1-1.3) 
59% 1.10 (1.0-1.2) 
72% 1.21 (1.1-1.4) 
46% 2.53 (2.3-2.6) 
7.1% 0.75 (0.6-0.9) 
*Adjusted Odds Ratio (Cardiology care vs Non-Cardiology) controlling for 17 patient 
clinical factors and 4 Hospital features (academic status, cath/PCl facilities, bed size, 
and % pts cared for by cardiologist). 
2:45 p.m. 
851-4 Are Patients Properly Informed Prior to 
Revascularization Decisions? 
Karen P. Alexander, Tina Harding, Laura Coombs, Eric Peterson, Duke Clinical 
Research Institute, Durham, NC 
Background: Ideally, the decision for invasive cardiac care is made after pt and doctor 
weigh the risks and benefits. Informed consent and good clinical practice require discus- 
sion of these risks and benefits, but the degree to which pts comprehend this information 
is unknown. 
Methods We surveyed 679 pts admitted for chest pain prior to decision for cardiac cath 
(CC) (mean age 69.4yrs, 46% female, 65% white, 56% high school grads). Followup sur- 
vey at 6 wks, asked pts to identify and quantify risks and benefits for PCI or CABG from a 
multi-choice list. 
Results: Overall, 65% had CC, 16% had PCI. and 6% had CABG. At follow-up, 94% of 
were satisfied with their decision, 93% felt it was their decision to make, 69% felt ade- 
quately informed, and 62% felt they understood risks and benefits. Still, when choosing 
from a list, 42% of pts could not identify any risks of PCI and 41% of pts could not identify 
any benefits from PCI (Table). For CABG, 45% of pts could not identify any risks, and 
22% of pts could not identify any benefits. When asked to quantify risks (from 0.01 to 
20%). 76% of PCI pts and 57% of CABG pts did not know. Pts who knew benefits of PCI 
and CABG had higher satisfaction with their decision (p=O.O3 and 0.006 respectively). 
Conclusion: The basic tenants of informed consent are not met as assessed by pt 
recall. Half of all pts are unable to recount risks or benefits, and 75% could not quantify 
them. Further investigation into optimum methods for information transfer to pts is war- 
ranted. 
Benefits of PCI Benefits of CABG 
Prolong Life 37% 66% 
Relieve Symptoms 46% 60% 
Prevent Heart Attack 36% 57% 
Do not know 42 % 22% 
3:oo p.m. 
851-5 Economic Burden of Nonischemic Congestive Heart 
Failure: Evidence From PRAISE-2 
Padma Kaul Linda Davidson-Ray, Patricia Cowper. Lawrence Liao, Daniel Mark, Duke -I 
Clinical Research Institute, Durham. NC 
To characterize long-ten costs associated with nonischemic congestive heart failure 
(CHF). we studied 1253 US patients enrolled in the PRAISE-2 trial (inclusion critena: 
NYHA class Ill or IV CHF of non-ischemic etiology). 
Hospttal billing data were collected as part of a prospective economic sub-study. Median 
follow-up was 2.2 years, during which 615 (65%) patients were hospitalized and 55 (4%) 
underwent cardiac transplants. Non-hospitalized patients were vounaer (median aae 56 
vs. 59 years), had higher ejection fractions (24% vs. 21%) and~shorter duration o;CHF 
H .6 vs. 3.1 vearsl and were less likely to be diabetic 116% vs. 22%) or classified as 
NYHA class IV (12% vs. 24%). Total hospltallzation cost for the cohort was estimated at 
over 29 million (US $, 2000); with transplant patients accounting for just under 25% of the 
total cost (Table). Excluding transplant patients, patients in highest cost quartile 
(>$32.000) were mc~re likely to be male (72% vs. 62%), classified as NYHA class IV 
(33% “s. 21%), have CHF as a result of alcohol dependence (32% “s. 19%), and have 
longer duration of CHF (5 vs. 4 years). 
Conclusion: Our study is the first to demonstrate the tremendous economic burden of 
non-ischemic heart failure. While waiting for cardiac transplants remains the major cost 
driver, duration and severity of disease are correlated with increased resource utilization 
and underlme the need for aggressive pharmacotherapy aimed at improving LV function 
in this population. 
‘~~0.05 for withln subgroup comparison 
Subgroup 
Total 
Age<75 years 
Age>75 years 
Female 
Male 
NYHA Ill 
NYHA IV 
N Death 
% 
125 31.5 
3 
113 30.2 
0 
123 43.9 
425 24.5’ 
626 35.1 
loo 26.0 
6 
246 45.9 
Ejection fraction <= 696 35.6’ 
25% 
Ejection fraction > 355 21.1 
25% 
No Transplants 119 32.1’ 
6 
Transplants 55 16.2 
Hospitalizatio Average Length of Average total 
n % stay cost 
65.0 20 $23,676 
63.4 21’ $24,739 
60.5 15 $15,951 
66.2 16 $23,676 
63.4 21 526,161 
61.7’ 20 522,092 
76.5 21 $31,092 
67.6 21’ $27,367. 
58.0 17 514,994 
63.4’ 17’ 516,657’ 
100 66 $139,068 
3:15 p.m. 
851-6 Regional Variation in Quality of Heart Failure Care: VA 
Versus Medicare 
Paul Heidenreich, Anita Deswal, Nelda Wray, VA Palo Alto Health Care System, Palo 
Alto, CA. Houston VA, Houston, TX 
We wished to determine if patient mix and/or hospital academic affiliation and board cer- 
tification rate were associated with the quality of heart failure (HF) care in the Veterans 
Affairs (VA) Health System. 
Methods. We determined compliance with three HF guidelines (ejection fraction (EF) 
measure, ACE inhibitors if EF < 40%, and warfarin if atrial fibrillation) for 13,255 outpa- 
tients through chart review at 135 VA hospitals. VAs were grouped as low (< median 
compliance for all measures) or high performers. We determined Council of Teaching 
Hospitals (COTH) membership and board certification rate for each VA. 
Results: The mean patient age was 70 years, 57% were white, and 33% had income < 
510,000 per year. Median (interquartile range) board certification at each VA was 74% 
(63-62) and 55% were COTH hospitals. Median guideline compliance was 67 (61-91) for 
ACEi use for EFc4O%, 93 (66-96) for EF measure, and 92 (62-100) for warfarin if atrial 
fibrillation. 25 (19%) hospitals were below the median on each measure. Lack of COTH 
affiliation and a low board certification rate (but not age, race or income) were associated 
with poor guideline compliance (Figure). In multivariate analysis, only COTH affiliation 
(p<O.OOOl) and board ceriification rate (p=O.Ol) were predictive of guideline compli- 
ance@ squared=0.22). 
Conclusion: Differences in academic affiliation and board certification rates explain VA 
hospital differences in compliance with heart failure guidelines more than differences in 
patient mix. 
